Acute Rheumatic Fever and Rheumatic Heart Disease: Sudan’s Guidelines for Diagnosis, Management and Control
Sudan’s Federal Ministry of Health
Sudan Heart Society-Working Group on Pediatric Cardiology
Sudanese Children’s Heart Society

Writing Committee:

Sulafa Khalid M Ali, FRCPCH, FACC, Consultant Pediatric Cardiologist
Professor-University of Khartoum

Mohamed Saeed Al Khaleefa, FRCP, Consultant Cardiologist
Professor-University of Al Zaem Al Azhari

Siragedeen Mohamed Khair, MD, Consultant Pediatrician
Professor- University of Al Zaem Al Azhari
## Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Preface</strong></td>
<td>4</td>
</tr>
<tr>
<td>Chapter 1</td>
<td>Rheumatic Heart Disease : General Considerations</td>
<td>5</td>
</tr>
<tr>
<td>Chapter 2</td>
<td>Streptococcal Pharyngitis</td>
<td>9</td>
</tr>
<tr>
<td>Chapter 3</td>
<td>Acute Rheumatic Fever</td>
<td>14</td>
</tr>
<tr>
<td>Chapter 4</td>
<td>Rheumatic Heart Disease</td>
<td>25</td>
</tr>
<tr>
<td>Chapter 5</td>
<td>Rheumatic Heart Disease in Pregnancy</td>
<td>50</td>
</tr>
<tr>
<td>Chapter 6</td>
<td>Acute Rheumatic Fever &amp; Rheumatic Heart Disease Control Program</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Rheumatic Heart Disease Protocols, Manuals, Brochures and Educational Websites</td>
<td>62</td>
</tr>
</tbody>
</table>
Preface:

Rheumatic heart disease (RHD) is a devastating sequel of acute rheumatic fever (ARF), initiated by a simple throat infection with group A streptococcus in susceptible population. Eradication of RHD can be achieved by improvement of health care system as has been witnessed in developed countries. In many developing countries like Sudan, RHD is still prevalent causing significant mortality and premature cardiovascular death as well as an undesired burden on the health system.

An RHD control program has been established in Sudan in 2012 aiming to increase the awareness of both the public and medical personnel, to introduce primary and consolidate secondary prevention and to strengthen the surveillance system.

This booklet serves as a reference for physicians and other health care providers containing relevant background knowledge and clinical guidelines for diagnosis, management and prevention of ARF and RHD. In addition, it contains brochures, awareness material as well as educational websites.

We hope that this book helps the medical community to have a better understanding for and management of ARF and RHD.

Khartoum in August 2015
Chapter 1

Rheumatic Heart Disease:
General Considerations
Introduction

Acute Rheumatic Fever (ARF) is an immune reaction to the group A streptococcus (GAS) pharyngitis. ARF mainly affects the joint, the heart, the skin and the central nervous system, however, all the manifestations resolve spontaneously except the cardiac affection which leads to chronic valve damage; rheumatic heart disease (RHD). RHD is the leading cause of acquired heart disease in young people all around the world but is highly prevalent in countries with poor socioeconomic state and health systems.

The global burden was found to be 471,000 annual cases of ARF, with the incidence of ARF in children ages 5 to 15 years ranging from 10 cases per 100,000 in industrialized countries to 374 cases per 100,000 in the Pacific region. The overall burden of RHD was estimated to be 15.6 million prevalent cases with 282,000 new cases and over 233,000 deaths per year (1).

Pathogenesis:

Although not fully understood, there is strong evidence that molecular mimicry between GAS antigen and human proteins lead to auto immune (humoral and cellular) mediated damage to heart valves. Cytokines are the likely effectors of valve damage, they can recognize M protein and then produce inflammatory mediators including tumor necrosis factor alpha, interferon and interleukins which cross react with cardiac myosin. Further evidence of inflammation is supported by high levels of advanced oxidation protein products and high sensitive C-reactive protein in plasma detected in patients with RHD. (2). This was well shown in Sudanese patients who were found to have a high level of cytokines and C-reactive protein even during the chronic phase of RHD) indicating an ongoing inflammatory process (3, 4).

Rheumatic Heart Disease: natural history:

Once ARF occurs, there is a very high rate of recurrence and the valve damage becomes evident. As early as 1965, it was found that the prognosis of patients who have established RHD was poor. While mild RHD may improve if recurrence of ARF is prevented by secondary prophylaxis, only 11% of those with established RHD will be free of heart failure at 10 years of follow up (5). Recurrence of ARF is the most important factor that determines the severity and prognosis of RHD.

Rheumatic Heart Disease in Sudan:

The incidence of clinical RHD (detected by auscultation) in Sudan was found to be 100 per 100000/year and the prevalence had been reported as 10.2 per 1000 compared with 2.3 per 1000 in Saudi Arabia and 5.1 per 1000 in Egypt. (6) These numbers are likely to be underestimated as in many developing countries echocardiography (echo) screening of school children revealed much higher prevalence rates. In India, it was shown that the prevalence of RHD by echo screening is 20 per1000,
several folds higher than clinical prevalence (7) Similar results found in Uganda, and Fiji had unmasked an extremely high prevalence of subclinical carditis(8,9). In Sudan’s main Children’s hospital s, RHD represent the most common cause of admission to cardiology wards and the most common cause of death due to cardiac disease. Ninety five percent of patients with RHD seen have severe forms of valve disease needing surgical intervention. Ninety percent of those with RHD do not have any history of ARF indicating that the first episode passed unnoticed and 50% of them were not compliant with secondary prophylaxis. Only 30% of patients came back for follow up indicating poor access to tertiary care and the need to decentralize services and raise public awareness (10).

The Ministry of Health (MOH) reported that in the year 2011 the total number of patients seen with ARF/RHD in outpatient clinics in the whole Sudan was 36877 (representing 13% of the global annual burden), out of them (11976) were seen in Khartoum state followed by Western States (Darfur and Kordofan) (9170) while the least number was seen in River Nile State (195) patients. The same report showed that 509 cases of RHD were admitted to hospitals, including 176 children between (5-14 years) . RHD caused 44 deaths in 2011(9%). (9).

These findings are similar to those derived from review of over 300 patients referred to Khartoum. The majority were found to be coming from Darfur area followed by Kordofan. In addition most patients residing in Khartoum are originally coming from those areas (10)

RHD surgery constitutes the most common type of cardiac operations in children and young adults in Sudan in all cardiac centers (Sudan Heart Center, Ahmed Gasim, Al Shaab and Medani Heart Centers), however, only 7% of those who need surgery get access to operations because of technical and financial constrains, the cost of surgery being 4000 US Dollars.

The post operative follow up poorly documented and likely to be inadequate, many patients don’t come back for follow up. Those who do come often present with complications of bleeding, cerebrovascular accidents, valve dysfunction and endocarditis. Recurrence of ARF is well documented after valve surgery due to the poor compliance with secondary prophylaxis.

Sudan needs to have special focus on early diagnosis, management and prevention of ARF and RHD targeting primary health care system in areas with high prevalence.

**Key Points:**

1. Sudan has a high prevalence of RHD especially in Darfur and Kordofan areas
2. Most patients with RHD have a severe form of disease needing surgery and have evidence of an on-going inflammation.
3. Surgery is not affordable in 93% of patients due to limited surgical resources and the high cost of surgical operations.
4. The limited access to health care leads to suboptimal use of secondary prophylaxis and anticoagulants.
References:

Chapter 2

Diagnosis and Management of Streptococcal Pharyngitis
Pharyngitis is a clinical syndrome associated with infection/irritation of the pharynx and/or tonsils. It is mostly viral, however, Group A beta hemolytic streptococcus (GAS) is the most common cause for bacterial pharyngitis all around the world, including Sudan, accounting for 25% of pediatric patients with sore throat (1). The diagnosis of streptococcal pharyngitis can either be clinical only or using clinical criteria supported by laboratory investigations. The gold standard diagnostic method is by using a Clinical Prediction rule (CPR) supported by rapid antigen test (RAT) and/or throat culture (2).

Importantly, antistreptolysin O titre (ASO) has no role in diagnosis of GAS pharyngitis as titers increase only 7 to 14 days after the onset of infection and remain high for weeks.

**Antistreptolysin O (ASO) titre has NO ROLE in diagnosis of acute pharyngitis**

**Limitations of Rapid Antigen Test and Throat Culture:**

1. The cost of both tests is high and RAT is not available in Sudan.
2. Many people are asymptomatic carriers (10% of school age children).
3. Sensitivity and specificity of both tests are not optimal.
4. The need to wait for days for the culture result prohibits its routine use.

As countries with RHD usually have low resources, a CPR can be used without doing RAT or throat culture in order to diagnose GAS pharyngitis.

**Which CPR to choose?**

Table 1 shows an example of CPR (3)

<table>
<thead>
<tr>
<th>Sore Throat and:</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever (temperature &gt;38°C)</td>
<td>1</td>
</tr>
<tr>
<td>Absence of cough</td>
<td>1</td>
</tr>
<tr>
<td>Cervical LN enlargement</td>
<td>1</td>
</tr>
<tr>
<td>Tonsillar swelling or exudates</td>
<td>1</td>
</tr>
<tr>
<td>Age 3 to &lt;15 yr</td>
<td>1</td>
</tr>
<tr>
<td>Score</td>
<td>Risk</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
</tr>
<tr>
<td>1</td>
<td>5 - 10%</td>
</tr>
<tr>
<td>2</td>
<td>11 - 17%</td>
</tr>
<tr>
<td>3</td>
<td>28 - 35%</td>
</tr>
<tr>
<td>4</td>
<td>51 - 53%</td>
</tr>
</tbody>
</table>

Another example is the one used in the original Integrated Management of Childhood Illness (IMCI) which states that the presence of fever or sore throat and 2 of the following: congested throat, tonsillar exudates or cervical lymph node enlargement, so it considers 3 points. However, when IMCI score was tested it was shown to be only 12% sensitive and 94% specific. It missed 88% of children with positive cultures (4).
A similar CPR was tested in Egypt and used only 2 points and found a sensitivity of 80% and specificity of 40%. Similar results were reported from Turkey (5, 6).

**Sudan’s Protocol for Sore Throat Management:**
Sudan’s MOH adopted a simplified approach to diagnose GAS pharyngitis with a CPR that utilizes the following:

1. Patients 4-18 years of age
2. Sore throat
3. No runny nose/cough

**Treatment of GAS Pharyngitis:**
The treatment of choice is one intramuscular injection of benzathine penicillin G (BPG). The dose is 600 000 IU for those less than 7 years and 1.2 million IU for those who are 7 years of age or more. Routine allergy testing is required (See guidelines in Physician and Medical Assistant’s Manuals).
In patients sensitive to BPG, oral erythromycin can be given for 10 days.
Tonsillectomy is indicated if there are frequent episodes of tonsillitis or there is tonillar hypertrophy with symptoms of upper respiratory tract obstruction.

**Tonsillectomy may decrease but does not eliminate the occurrence of GAS pharyngitis.**
Health Education:
Families should be informed about:
1. The symptoms of GAS pharyngitis.
2. The serious consequences of untreated pharyngitis i.e. ARF and RHD and the need to consult medical personnel as early as possible to avoid complications.
3. The need to avoid pharyngitis by improving house ventilation and hygiene and avoid crowding.

Key Points:

1. Diagnosis of GAS Pharyngitis is clinical by finding of sore throat without runny nose/cough in patients 4-18 years of age.
2. Treatment of GAS Pharyngitis is: One intramuscular injection of Benzathin penicillin.
3. Families need to be educated about the complications of GAS pharyngitis

References:

Sudan’s Protocol for Management of sore throat
Chapter Three
Acute Rheumatic Fever
Introduction:

Acute rheumatic fever (ARF) is a multisystemic autoimmune disease that involves mainly the joints, the heart and the brain and rarely the skin. It takes place 2-3 weeks after an infection of upper respiratory tract with Lancefield group Aβ haemolytic streptococci (GAS). Streptococcal skin infection rarely been implicated in the disease process (1, 2).

ARF, like streptococcal infection occurs commonly between the ages of 5-15 years. It is rare in children under three years of age and adults, the peak incidence of first attack is between 6-8 years (3). In Sudan, ARF has been reported in patients 5 years of age or younger in 10% of patients (4).

Male to female ratio is similar regarding the overall incidence of ARF. While chorea and mitral valve disease are common in females, aortic valve disease is more common in males. ARF and RHD have been found in nearly every ethnic group. It is a worldwide phenomenon, and in every country its frequency is a function potentiated by crowding and poverty. In cold climates in the past, there were two peaks of ARF in late winter and in autumn, but the difference is not marked in warm countries, other authors reported highest peak in winter and spring months in cold climate countries and this may be related to increased opportunity to spread streptococcal infection in cold and damp months. Prevention provided the most direct evidence showing that the relationship between GAS and ARF is casual rather than coincidental (2).

Nearly half a million people worldwide suffer an episode of ARF each year and at least 15 million people live with subsequent valve damage of RHD. Robust epidemiologic data for ARF and RHD is insufficient; the true burden of disease is likely to be several times higher than current estimates. Approximately half a million people die of RHD annually around the world. These deaths are premature; on average, people dying from RHD are below the age of 40 years (5).

Clinical Features of Acute Rheumatic Fever:

In one third of patients the streptococcal infection passes unnoticed and 54 to 70% of recurrences of ARF were caused by asymptomatic streptococcal infection. A latent period, the interval between the onset of symptoms of streptococcal infection and symptom of RF, duration may be 1-5 weeks, and in chorea may be 2-6 months (1).

Jones Criteria: 2015 Modification:

The American Heart Association published the revised Jone’s Criteria endorsed by the World Heart Federation. (table 1)(ref 6)
Important Modifications of Jones Criteria 2015

1. Inclusion of subclinical carditis (echo diagnosed) as a major criteria.

   **ECHO SHOULD BE DONE TO ALL PATIENTS WITH SUSPECTED ARF**

2. Consideration of the patients origin: in patients from **high risk areas** (defined by a prevalence of RHD more than 1 per 1000 or incidence > 2 per 100 000 per year) ARF is diagnosed using less strict criteria.

3. In high risk settings, **monoarthritis and polyarthralgia** are considered as **Major Criteria** and **monoarthralgia a minor criteria**.

4. Degree of fever and ESR in high risk areas is less than in low risk areas.
   
   (Ref 6)

---

**Table 1**

2015 Modification of Jones Criteria

| A. For all patient populations with evidence of preceding GAS infection |
|---|---|
| **Diagnosis:** initial ARF | 2 Major manifestations or 1 major plus 2 minor manifestations |
| **Diagnosis:** recurrent ARF | 2 Major or 1 major and 2 minor or 3 minor |

<table>
<thead>
<tr>
<th>B. Major criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Low-risk populations</strong>*</td>
</tr>
<tr>
<td>Carditis†</td>
</tr>
<tr>
<td>• Clinical and/or subclinical</td>
</tr>
<tr>
<td>Arthritis</td>
</tr>
<tr>
<td>• Polyarthralgia only</td>
</tr>
<tr>
<td>Chorea</td>
</tr>
<tr>
<td>Erythema marginatum</td>
</tr>
<tr>
<td>Subcutaneous nodules</td>
</tr>
<tr>
<td><strong>Moderate- and high-risk populations</strong></td>
</tr>
<tr>
<td>Carditis</td>
</tr>
<tr>
<td>• Clinical and/or subclinical</td>
</tr>
<tr>
<td>Arthritis</td>
</tr>
<tr>
<td>• Monoarthritis or polyarthritis</td>
</tr>
<tr>
<td>• Polyarthralgia†</td>
</tr>
<tr>
<td>Chorea</td>
</tr>
<tr>
<td>Erythema marginatum</td>
</tr>
<tr>
<td>Subcutaneous nodules</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C. Minor criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Low-risk populations</strong>*</td>
</tr>
<tr>
<td>Polyarthralgia</td>
</tr>
<tr>
<td>Fever (≥38.5°C)</td>
</tr>
<tr>
<td>ESR ≥60 mm in the first hour and/or CRP ≥3.0 mg/dL§</td>
</tr>
<tr>
<td>Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion)</td>
</tr>
<tr>
<td><strong>Moderate- and high-risk populations</strong></td>
</tr>
<tr>
<td>Monoarthralgia</td>
</tr>
<tr>
<td>Fever (≥38°C)</td>
</tr>
<tr>
<td>ESR ≥30 mm/h and/or CRP ≥3.0 mg/dL§</td>
</tr>
<tr>
<td>Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion)</td>
</tr>
</tbody>
</table>
Major Manifestations:

1. Carditis:

Occurs in 40% of patients during the first attack and almost 100% if ARF recurs. It may be the only major manifestations and usually appears in the first week of the illness.

Patients typically present with heart murmurs. Heart failure ensues if the valve regurgitation is severe, or can be asymptomatic if the valve affection is mild. Tachycardia presenting during sleep, disproportionate to fever or persisting after the control of fever is highly suggestive of carditis. In patients suspected with ARF, without heart murmurs, echo should be done to exclude subclinical carditis.

Murmurs Heard In ARF: (see also chapter 4)

An organic apical pan-systolic murmur due to mitral regurgitation (MR) is the commonest murmur in ARF. This is sometimes accompanied by apical mid-diastolic (Cary Coombs) murmur denotes mitral valvitis and should be differentiated from that of mitral stenosis which does not occur in the acute phase.

Basal diastolic murmur of aortic regurgitation (in the second aortic area) can be present, usually associated with MR and occasionally isolated.

Mitral stenosis is a late manifestation of ARF, which are not present in the acute phase. Arrhythmias such as delayed AV conduction (see below) is common but does not necessarily indicate carditis. Nodal rhythm and atrial fibrillation are rarely caused by ARF.

Pericarditis manifested by a pericardial rub can rarely be present.

Diagnosis of Carditis:

Rheumatic carditis is diagnosed when there is clinical or echo evidence of valvitis with or without pericarditis.

The old theory that ARF causes histopathological pancarditis has been refuted by the finding that the rheumatic process does not involve the myocardium but rather affects the endocardium. This fact is supported by the absence of clinical myocarditis (7).

Subclinical carditis (SCC):

SCC is pathological valvular regurgitation/stenosis detected on echocardiography that is not evident clinically. With better definition of echocardiographic criteria for SCC that was recently published by World Heart Federation group, American Heart Association has now accepted SCC as a major manifestation (see below and see chapter 4) (8,6).
2. Arthritis:

Characteristically involves multiple big joints and is migrating. It is unusual to involve the central joints as spines, hips and the peripheral ones as the fingers and toes. Infrequently it involves the tempromandibular joint. Severe pain with inability to move the joint is characteristic. The pain continues for 1-2 days then flits to the other joint. Examination of the joint reveals tenderness, swelling, heat and redness.

Monoarthritis or nonflitting polyarthritis can rarely occur and has been recently included as major criteria in high risk population and monoarthralgia included as a minor criterion. (See modified Jones Criteria 2015 above)

Arthritis typically improves dramatically with aspirin and is a self limiting condition without permanent sequelae.

3. Subcutaneous nodules:

Subcutaneous nodules are not pathognomonic of ARF as they occur in rheumatoid arthritis and systemic lupus. They rarely occur as isolated manifestation but most often with severe carditis appearing several weeks after its onset. They are round, firm, painless, 0.1 – 1cm in diameter sited over the bone prominences and over tendons, with overlying skin being mobile and not inflamed. They occur particularly over the extensor tendons of the fingers and toes and flexors of the wrists and ankles. They occur in crops and vary in numbers from one to usually three or four dozen. When numerous, they tend to be symmetrical. Their duration last for a week or two and rarely more than a month, and sometimes disappear within several days.
4. Erythema Marginatum:

Occurs in 10% of patients with ARF commonly with other manifestations. The lesions are pink often slightly raised macules that fade centrally and coalesce to form serpiginous patterns. It usually occurs in the covered parts and may be manifested by local application of heat. They disappear within hours and may appear intermittently within weeks to months (9).

5. Chorea (Sydenham, St Vitus Dance):

It is involuntary purposeless movements, usually bilateral but sometimes unilateral that develops gradually over weeks. It is variable from being slight, brought about by excitement or conscious effort to being so violent that may result in self injury. It occurs most often in pre-pubertal girl and rarely among adults in either sex.

Chorea may occur as the only clinical signs or may precede, follow or exist concomitantly with other manifestations of ARF. Speech and handwriting abnormalities are common. Serial handwritings can be used to detect and follow up progress of the disease.

There is a difficulty in counting rapidly and maintaining the protrusion of the tongue. There is also hyperextension of the fingers and wrist when the arms are held extended over the head. The hand grip is weak and there may be intermittent muscular contractions or twitches. Patellar response shows a hung up type of response. Emotional liability is marked as is shown by inappropriate bouts of crying or laughter.

Minor manifestations:

1. Fever:

It is almost invariably present in the early stage, except in patients whose only manifestation is chorea or those receiving salicylates or steroids. It often becomes low grade after the first week and may persist at this level for 2-4 weeks.

2. Arthralgia:

Pain without objective changes of swelling, heat and redness may occur in some joints. Myalgia is rare. Arthralgia should not be counted as minor when arthritis is counted as major criteria. In high risk population, polyarthralgia is a major criterion and monoarthralgia a minor one.

3. Acute phase reactants:

Include elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are commonly raised in ARF. In high risk areas ESR > 30 mm/hr is considered as a minor criterion.

4. Prolonged PR interval:

Prolonged PR interval (first degree heart block) alone does not constitute evidence of carditis or predict long term cardiac sequelae and is transient. It should not be considered when carditis is counted as a major manifestation. Rarely, complete (3rd degree) heart block may occur.

Other Findings:
Include history of recent sore throat, family history of ARF, abdominal pain, epistaxis, tachycardia, rheumatic pneumonia, anemia, chest pain, weight loss and malaise.

**Post Streptococcal Psychiatric Disorder:**

Clinical & research findings in both immunology & neuropathology have established the existence of post streptococcal neuropsychiatric disorders. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) is acronym applied to subgroup of children with obsessive-compulsive or tics disorders occurring in association of streptococcal infections. In addition, there are recent reports of dystonia, chorea, encephalopathy and dystonic choroaesthesia occurring as sequacae of streptococcal infections (10).

**Recent Evidence of Group A Streptococcal infection:**

For diagnosis of ARF there should be an evidence of recent GAS infection. It includes raised tites of antistreptolysin O (ASO), anti DNase B and antihyalurindase. About 80% of patients with ARF have elevated ASO; however, 95-100% have elevation if the three different antibodies are measured. (11). Evidence also includes a positive throat culture for (GAS), recent scarlet fever, and rapid antigen test for GAS.

**Diagnosis of ARF:**

For diagnosis of ARF in new patients, the revised Jones criteria should be adhered to which states that **one major and two minor criteria or two major criteria plus recent evidence of GAS infection.**

For diagnosis of ARF in patients known to have RHD: **one major or two minor criteria are needed plus recent evidence of GAS infection.**

---

**New Episode**

- 2 Major Criteria
- OR
- 1 Major + 2 Minor Criteria
- + High ASO

**Recurrent Episode**

- 1 Major Criterion
- OR
- 2 Minor Criteria
- +
- High ASO

**Probable (atypical) ARF**

- Fewer criteria
- Atypical (e.g. mono or poly) arthritis
- + High ASO
Special Situations:

1. Probable (Atypical) ARF:

Patients may present with non-flitting polyarthritis, polyarthralgia or monoarthritis and with several (3 or more) other minor manifestations, together with evidence of recent GAS infection. Some of these cases may later turn out to ARF. It is prudent to consider them as case of probable ARF (once other diagnoses are excluded) and advice regular secondary prophylaxis; such patients require close follow up and regular examination of the heart. This cautious approach is particularly suitable for patients in vulnerable age groups in high incidence settings (6).

2. Chorea:

Often presents without other manifestations and patients should be started on secondary prophylaxis.

3. Insidious (indolent) Carditis:

Slowly progressive valve damage without history of ARF is common in endemic countries and these patients are high risk as the valve damage has already started. Strict secondary prophylaxis is needed.

Treatment of ARF:

1. Antibiotics:

A single intramuscular injection of benzathine penicillin G (BPG) to eradicate GAS from upper respiratory tract. The dose is 600 000 IU for those less than 7 years and 1.2 million IU for those who are 7 years of age or more. Routine allergy testing is required (See guidelines in Physician and Medical Assistant’s Manuals).

After this initial course of antibiotic therapy the patient should be started on long term secondary prophylaxis. Duration of secondary prophylaxis is for life in case of RHD and up to 25 years of age if there is no carditis.

2. Anti inflammatory therapy:

Patients should be treated with oral salicylates. The usual dose of aspirin is 75 mg/kg/24 hrs divided q.i.d. PO for 4 wk then tapering according to the acute phase reactants. Aspirin should be given after meals.

Indications for Steroids:

There is little evidence that steroids are superior to salicylates. (12). Steroids can be considered in the following situations:

1. Patients who do not tolerate aspirin.
2. Patients who fail to show improvement (by clinical or acute phase reactants) with aspirin

   The usual dose is 2 mg/kg/day divided 6 to 8 hourly for 2 weeks followed by tapering of the dose by 5 mg/day every 2-3 days. At the beginning of tapering the dose aspirin should be started at dose of 60 mg/kg/day divided qid for 6 wk keeping a period of overlap.

3. Supportive Treatments:

Supportive therapies for patients with moderate to severe carditis include fluid & salt restriction, diuretics and angiotensin converting enzyme inhibitors. Physicians need to consult cardiologists.

**Treatment of Sydenham’s chorea:**

   Anti-inflammatory agents are usually not indicated. Sedatives may be helpful early in the course of chorea. Haloperidol (0.01-0.03 mg/kg/day divided bid PO) or chorpromazine (0.5 mg/kg 4-6 hr PO) should be initiated and continues for 3-4 months.

**Prevention of ARF: (also see chapter 6)**

   Depends on eradication of group A streptococci from upper respiratory tract. It is divided into:

**Primordial Prevention:**

Improving socioeconomic conditions, nutrition, housing conditions (decreasing crowding) and improving access to health care can all decrease the incidence of ARF.

**Primary Prevention:**

Prompt treatment of GAS pharyngitis with one injection of IM BPG is highly effective in preventing first attacks of ARF. However, about 1/3 of patients with ARF do not recall preceding episode of pharyngitis

A vaccine for GAS is being developed but has not yet been used in clinical practice (see chapter 6)

**Secondary Prevention:**

Secondary prevention requires continuous BPG administration, which should begin as soon as the diagnosis of ARF is made. For those with no evidence of carditis in their initial attack should receive BPG every three weeks up to 25 years of age; however those with evidence of RHD should receive it for life. The interval of 3 weeks has been questioned and some countries are administering BPG every 2 weeks. To modify the protocol, BPG brands should be tested to confirm their bioavailability.

**BPG Quality:**

In developed countries, good brands of BPG do not require skin testing as the purity of the drug is assured while in developing countries bearing the burden of ARF/RHD, BPG purity has been questioned. (13)
Therefore, countries need to work on importing high quality BPG and test its bioavailability in order to determine the secondary prophylaxis interval and allergenic properties.

The doses are the same as for primary prevention. In cases of documented sensitivity to penicillin, erythromycin can be given as 250 mg (below 7 years of age) and 500 mg (above 7 years of age) PO BD for the same period.

**Improving Medical Personnel and Public Awareness:**

ARF is considered to be a neglected disease even in endemic countries, therefore continuous training of physicians and public awareness campaigns need to be conducted in order to improve its recognition and management. (14)

---

**Key points:**

- Modified Jones Criteria for 2015 included subclinical carditis as a major and polyarthralgia and monoarthritis as major criteria in high risk regions. Monoarthralgia is included as a minor criteria in high risk settings.
- Diagnosis of recurrent episode of ARF utilizes **less criteria** than the first episode and should be made if there are one major or 2 minor criteria with positive ASO
- In highly endemic areas if criteria are short of ARF, **probable** ARF needs to be considered and benzathine prophylaxis instituted.
- Benzathine penicillin, salicylates and supportive treatment should be started in patients with ARF
- Secondary prophylaxis should continue for life in case of RHD and up to 25 years of age if no carditis.
- Strict follow up is needed to assure adherence of patients to secondary prophylaxis

---

**References**

1. Abdel Rahman SMK. Rheumatic fever with special reference to prevention and recommendations to Sudan, written document presented within the collaborative program between Uppsala University Hospital and Ministry of Health, Sudan, International Child Health Unit, Uppsala, 1985.


Chapter 4

Rheumatic Heart Disease
ARF is associated with carditis in 50-75% of patients with the first episode, the rate of carditis increases significantly with recurrence of ARF hence the importance of secondary prophylaxis. Rheumatic carditis affects mainly the heart valves. Although by histopathology the myocardium and pericardium may show the Aschoff nodules, the characteristic lesions of RHD, however, clinical symptoms and signs are mainly due to valvular involvement.

The most common valves affected are the mitral and aortic valves. In Sudanese patients, isolated mitral regurgitation (MR) is reported in about 40%, followed by combined MR and aortic regurgitation (AR) in 35%, combined MR and mitral stenosis (MS) in 7%, isolated AR in 4% and isolated MS in 3%. In about 11% of patients, combination of more than 2 valves was detected. (1).

In older children and adults, stenotic lesions become more dominant, aortic stenosis is rare in all ages. In another cross sectional study MS was found to be 9% and all the patients were found to be older children with severe disease, the postulation was that mild MS may be missed by clinical examination as it is asymptomatic and the signs are subtle. This is supported by the finding that MS is the commonest lesion in young adults which indicates low rate of detection in children (2).

**Types of RHD:**
Rheumatic carditis can be categorized into subclinical and clinical types. Recently, echo screening of asymptomatic school children revealed a very high prevalence of subclinical carditis, up to 10 times the clinical RHD (3).
Subclinical Carditis

Definition:
“The echocardiographic diagnosis of RHD in asymptomatic patients without audible murmurs”

Echo diagnosis of RHD without heart murmur can be made in 2 situations:
A: RHD discovered during screening programs at community level.
B: RHD discovered on screening in patients with ARF (e.g. with arthritis or chorea): in this situation we have a lower threshold to diagnose subclinical carditis.

Subclinical carditis detected on screening of school children utilized strict guidelines published by the World Heart Federation (4). Although long term follow up of such patients had so far shown a favorable outcome, guideline are still not well developed and more follow up time is needed. (5). Sub clinical echo-diagnosed RHD in the setting of screening programs is divided into 2 types:

1. Definite RHD
2. Borderline RHD

(See tables 1-3 -Ref 3)

Echocardiographic types of Subclinical Carditis

<table>
<thead>
<tr>
<th>Definite RHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Pathological MR and 2 morphological features of RHD</td>
</tr>
<tr>
<td>2. MS mean gradient 4 mmHg or more</td>
</tr>
<tr>
<td>3. Pathological AR and 2 morphological features of RHD</td>
</tr>
<tr>
<td>4. Borderline disease of both AV and MV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Borderline RHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Two Morphological features of MV</td>
</tr>
<tr>
<td>2. Pathological MR</td>
</tr>
<tr>
<td>3. Pathological AR</td>
</tr>
</tbody>
</table>
Morphological Features of Mitral and Aortic Valves

**Morphological Features of Mitral Valve**
1. AML >3 mm
2. Chordal thickening
3. Restricted leaflet motion
4. Excessive leaflet tip motion in systole

**Morphological Features of Aortic Valve**
1. Irregular/focal thickening
2. Coaptation defect
3. Restricted leaflet motion
4. Prolapse

Doppler Features of Pathological MR and AR

**Pathological MR**
1. Seen in 2 views
2. Jet length 2 cm or more
3. Velocity 3m/s or more
4. Pan systolic jet

**Pathological AR**
1. Seen in 2 views
2. Jet length 1cm or more
3. Velocity 3 m/sec or more
4. Pan diastolic jet

Management of Subclinical Carditis:

In the setting of screening programs, individuals with definite RHD need to be started on BPG prophylaxis in the same protocol of clinical RHD.

In borderline RHD, patients should be closely monitored by echo every 6 months to determine the progression of echo abnormalities and the need for prophylaxis.

In Sudan, echo screening will be used:

1. As a research tool to measure the prevalence of RHD
2. For early detection in highly endemic areas order to start secondary prophylaxis for definite cases.
Clinical Rheumatic Carditis

Patients with clinical carditis almost always present with heart murmurs, depending on the severity of valve dysfunction, variable degrees of heart failure ensue. Initial presentation can be with other features of ARF (arthritis, chorea) but many patients deny any history of preceding ARF.

Pathophysiology of RHD:

Involvement of the valves is the fundamental issue of RHD which affects mainly the mitral and aortic valves. Clinically, it presents with features of pulmonary congestion or left heart failure (LHF) initially, then it may progress with time to develop pulmonary hypertension (PHT) and right sided heart failure (RHF) with features of both LHF and RHF i.e. congestive heart failure (CHF) then with the progression of PHT the features of pulmonary congestion may diminish and the picture becomes that of severe RHF and end stage cardiac disease.

Symptoms start with shortness of breathing associated with cough, frothy sputum (LHF) that may be accompanied by hemoptysis. However with the ongoing pulmonary congestion the pulmonary vascular bed reacts by hypertrophy to protect the lungs from the pulmonary edema, this will result in increased pulmonary vascular resistance so the symptoms of cough, frothy sputum and hemoptysis may became less with the progression of the PHT while the symptoms of RHF (swelling of the lower limbs due to systemic venous congestion and its associated symptoms of abdominal pain and dyspepsia due to the congestion of the portal circulation) may ensue leading to features of CHF.
Clinical Features:

Symptoms:

*Congestion: Pulmonary:* cough, shortness of breathing. *Systemic:* abdominal discomfort, lower limb edema

*Low Cardiac Output & compensatory mechanisms:*

- Palpitations (could be atrial fibrillation), sweating, fatigue.
- **Systemic embolization:** hemiplegia

Signs (see diagrams below)

- Isolated MR
- MR with AR
- Isolated AR
- Isolated MS
- MR/MS
- TR/TS and AS: rare

**Systemic embolization:** hemiplegia
Typical Physical Signs of Severe MR:

Small volume pulse

Typical Physical Signs of Severe AR:

a) Large volume and collapsing pulse in addition to the other peripheral signs of the wide pulse pressure e.g. Corrigan’s sign.

b) High systolic BP with a pulse pressure more than the diastolic pressure.
Typical Physical Signs of Severe MS:

Heart rate is often irregular with atrial fibrillation

Signs of aortic stenosis may include:

- Small volume and slow rising pulse.
- Low blood pressure.
- Forceful and sustained apex beat which may be slightly displaced.
- Systolic thrill over the aortic area.
- Opening click of the aortic valve.
- Mid- systolic, high pitched & rough murmur.
- Muffled S2.
- S4.

Acute Decompensation:

Decompensation indicates severe RHD and reflects the status of the current presentation (the lesion plus the precipitating factor).

Causes of Decompensation:
1. **Recurrence of ARF**: related to discontinuation of secondary prophylaxis is the most common cause of decompensation in young patients.

2. **Volume overload**
   - Loss of volume control by discontinuation of medications “diuretics and vasodilators”
   - Causes of hyper dynamic circulation e.g. fever, anemia, pregnancy.

3. **Pressure overload**
   - Sudden rise in blood pressure.
   - Pulmonary embolism.

4. **Intrinsic pump problem**
   - Systolic dysfunction: related to long standing valve regurgitation
   - Diastolic dysfunction: e.g. rapidly accumulating pericardial effusion.

5. **Arrhythmias:**
   a. **Tachyarrhythmia**: Fast atrial fibrillation [AF].
   b. **Brady arrhythmia**: Could be related to drugs that slow the heart e.g. B Blockers and Digoxin

   The following precipitating factors are more relevant to RHD:
1- Discontinuation or non compliance with anti failure medications , the problem is even more serious with warfarin treatment (thrombotic or bleeding complications) or secondary prophylaxis with penicillin( progression of disease with recurrent ARF)

2- As these patients are of low socioeconomic status they are prone to recurrent infections and febrile illnesses. Fever is serious and correct diagnosis is essential for the cause of fever which may addressed in three categories:
   a- Recurrence of ARF (see above) it may be the initial presentation or as a precipitating factor and it indicates lack of secondary prophylaxis and may aggravates the lesion.
   b- Endocarditis (may be acute or sub acute) serious complication which may lead to rapid deterioration and destruction of the valve and may need urgent intervention

**Endocarditis is common with regurgitant lesions and rare in mitral stenosis**

Assessment of Severity:

**Group 1: Severe lesion but the patient is asymptomatic:**
- This may be encountered more with Stenotic lesions (MS and AS), symptoms may be late and the patient may show rapid downhill course when they appear.
- Careful history may reveal subtle symptoms
- They may need intervention to decrease morbidity and mortality.

**Group 2: Severe lesion and symptomatic:**
- Needs intervention at the right time before developing resistant heart failure and adverse surgical outcome measures.

**Objective Assessment of Severity:**

This may be assessed with great accuracy by physical signs (see above) and basic investigations (Echo, CXR and ECG)

**CXR**
- The primary role is to assess the heart size and the pulmonary vascular bed.
- Cardiomegaly is defined as the greatest transverse cardiac diameter > ½ the chest diameter

**The pulmonary vascular bed:**
This can be affected in four ways:

1- Pulmonary congestion.
2- Pulmonary plethora.
3- Pulmonary hypertension.
4- Pulmonary oligemia.

In regard to RHD pulmonary congestion and hypertension are important as mitral and aortic valves lesions lead to increased LA pressure which leads early to pulmonary congestion and eventually to pulmonary hypertension.

**PULMONARY CONGESTION**

Pulmonary congestion is defined as increased pulmonary venous pressure due to high left atrial (LA) pressure (Passive congestion).

There are three grades of pulmonary congestion:

**Grade 1:** Upper lobe diversion:

The veins of the upper lobes will become prominent due to increased vascularity of the upper lobes (which are well aerated) this correlates with pulmonary wedge pressure PWP of 15—20 cm water.

**Grade 2:** Interstitial edema:

Evident as Kerly B lines, this correlates with PWP of 20—25 cm water.

**Grade 3:** Frank alveolar edema:

Fluffy white patches and butterfly shadow radiating from the hila, this correlates with PWP > 25 cm water.
Pulmonary Hypertension:

This is evident on CXR as prominent pulmonary hila due to enlarged pulmonary arteries plus peripheral pruning (cutting) of the pulmonary circulation.

So the main indication of taking a chest x ray in a patient with RHD for the follow up patient is to assess the pulmonary vascular bed and to detect the signs of transition form of pulmonary congestion to pulmonary hypertension so as to interfere at the right time as severe pulmonary hypertension increases the operative risk and makes the long term prognosis less promising.

ECG

- To assess chamber enlargement or hypertrophy
- To assess the rhythm e.g. AF
- Effects of drugs e.g. Digitalis

Echo: Echo is the main tool for assessing valvular lesions. In RHD Echo is important to:

- Confirm the diagnosis of RHD
- To assess the severity of the lesion (see below)
- To assess prosthetic valves’ function
- Detect pericardial effusion (due to AFR or severe heart failure)
- Detect vegetations
- Left atrial echo contrast/ clots

Assessment of Valve Dysfunction: (Simplified Approach)

Mitral Regurgitation severity

<table>
<thead>
<tr>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
</table>
| • Small central jet $<4 \text{ cm}^2$ or $<20\%$ of LA area  
  • Vena contracta width $<0.3$ cm  | • Signs of MR$>$mild present, but no criteria for severe MR  | • Vena contracta width $\geq 0.7\text{ cm}$ with large central MR jet (area $< 40\%$ of LA) or with a wall-impinging jet of any size, swirling in LA  
  • Systolic reversal in pulmonary veins  
  • Prominent flail MV leaflet or ruptured papillary muscle. |
Mitral stenosis severity:

<table>
<thead>
<tr>
<th></th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valve area (cm²)</td>
<td>&gt;1.5</td>
<td>1.0-1.5</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Mean gradient (mmHg)</td>
<td>&lt;5</td>
<td>5-10</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Pulmonary artery</td>
<td>&lt;30</td>
<td>30-50</td>
<td>&gt;50</td>
</tr>
<tr>
<td>pressure (mmHg)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Aortic regurgitation severity:

<table>
<thead>
<tr>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Jet, width &lt; 25% of LVOT&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Intermediate values</td>
<td>Central Jet, width ≥ 65% of LVOT&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Vena contracta &lt; 0.3 cm</td>
<td></td>
<td>Vena contracta &gt; 0.6cm&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pressure half-time &gt; 500 ms</td>
<td></td>
<td>Pressure half-time &lt; 200 ms</td>
</tr>
<tr>
<td>Normal LV size</td>
<td></td>
<td>Holodiastolic aortic flow reversal in descending aorta</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate or greater LV enlargement</td>
</tr>
</tbody>
</table>
Assessment of AS severity:

<table>
<thead>
<tr>
<th>Aortic sclerosis</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic jet velocity (m/s)</td>
<td>≤2.5 m/s</td>
<td>2.6-2.9</td>
<td>3.0-4.0</td>
</tr>
<tr>
<td>Mean gradient (mmHg)</td>
<td>≤20 (&lt;30)</td>
<td>20-40 (30-50)</td>
<td>&gt;40 (50)</td>
</tr>
<tr>
<td>AVArea (cm²)</td>
<td>&gt;1.5</td>
<td>1.0-1.5</td>
<td>&lt;1</td>
</tr>
</tbody>
</table>

(Modified from: Classification of valve stenosis and regurgitation http://www.echopedia.org/wiki/Classification_of_valve_stenosis_and_regurgitation)

Assessment of Left Ventricle Function and Pulmonary Pressure:

Ejection Fraction (EF) needs to be measured and carefully monitored by echo. EF is usually high normal in patients with valve regurgitation. Decreasing EF is an indication for surgery and a low/normal EF is a surgical risk factor that may not improve after the operation.

Measurement of pulmonary artery systolic pressure from the tricuspid valve regurgitation velocity helps to assess the severity of the lesion and the timing as well as risk assessment of surgery.

Management of RHD:

At the time of first presentation:

First step is to make sure that there is no active disease:
Do ESR, CRP, ASO titre and consider recurrence of ARF is there is a major or 2 minor criteria and positive ASO. If there is active disease, anti inflammatory therapy should be started till the acute phase reactants return to normal (4-6 weeks) and the patients should be re evaluated at that time.
Goals of Management:

At Risk
- Pharyngitis
- Crowding
- Unaware

Early RHD
- ARF
- Discovered on screening

Established RHD
- Severe lesion

Primordial and Primary Prevention
Increasing Awareness

Secondary Prophylaxis
Early detection

Tertiary Prevention
Improving symptoms and decrease mortality

It should be emphasized to the patients that they should continue benzathine penicillin prophylaxis for life
The most common problems faced in treating patients with RHD are:
1. It is a disease of childhood and young adults
2. It is a disease of low socioeconomic communities.
3. Recurrence of rheumatic activity, on-going inflammation and failure to control factors of volume overload and hyper dynamic circulation may lead to severe disease that mandates early intervention in childhood as well as it may lead to failure of valve repair.
4. Endocarditis in patients with prosthetic as well as native regurgitant valves.
5. Treatment (both surgical and catheter-based) is expensive and at best is still palliative, as all of them have limited longevity.
6. Problems of monitoring anticoagulation treatment in patients with prosthetic valves or AF, leading to cerebro-vascular accidents (CVA) due to thrombosis/bleeding.
7. Grown up children and adults may need redo surgery due to valve mismatch.

Medical treatment:
- CHF needs to be managed with diuretics, angiotensin converting enzyme inhibitors (ACEI) and spironolactone.
- Digoxin can be added to patients with severe hemodynamic compromise or atrial fibrillation.
- Patients with atrial fibrillation should be started on beta blockers/digoxin and anticoagulation.
Management of patients with severe heart failure:
Patients may present with features of cardiogenic shock including tachypnea, dizziness or loss of consciousness, low blood pressure and multisystem failure.

Signs of edema and raised jugular venous pressure in the presence of hypotension should alert the physician to **cardiogenic shock.**

- Intensive care unit admission if possible, for cardio respiratory, blood gas, urine output and renal function as well as other system function monitoring.
- ECG, pulse oximetry and when feasible central venous pressure and arterial (invasive) blood pressure monitoring, if not available non-invasive blood pressure can be used.
- Low systolic pressure needs to be managed by inotropic support e.g dopamine 5-10 microgram /kg/minute. This helps to increase blood pressure but will increase systemic vascular resistance therefore it needs to be combined with dobutamine at similar dose, the latter causes peripheral vasodilatation and inotropy with minimal chronotropy.
- Intravenous furosemide needs to be started, patients with massive edema benefit from infusion of frusemide, they need to be monitored for hypokalemia. Potassium sparing diuretics needs to be added.
- Urgent surgical referral is needed.
Palliative and prognostic treatment

- Interventional treatment for RHD is regarded as ‘good Palliation’ as most procedure are associated with a high rate of reintervention.

- As the disease starts in childhood every effort should be done to delay the intervention (importance of secondary prophylaxis and control of factors leading to decompensation).
- Patients should be followed carefully by Echo to determine the right time for intervention (late intervention carries high operative risk and less favorable prognosis.

Indications for intervention

1. Asymptomatic Patients:
   Asymptomatic patients with severe valvular lesion (see Echo criteria for severity) should be closely monitored to decide the appropriate time for intervention.

   The following are indications for intervention:
   - Severe Pulmonary hypertension.
   - For regurgitant lesions (MR and AR), decrease in LV ejection fraction or Increasing in LV dimensions especially LV end systolic dimension.
     Importantly, when the ejection fraction approaches 50% progression of heart failure and death occur in up to 25% of these patients per year if surgery is not performed (cardiomyopathy secondary to MR). When surgery is performed in patients with ejection fraction less than 50% the 10 year survival is only 30% compared to 100% for those whose ejection fraction is 60%.
   - Severe MS.

2. Symptomatic patients:
   Symptomatic patients with severe valve dysfunction should be referred for intervention.

Treatment options

1. Valve repair
   - This is done mainly for MR but needs careful assessment by Echo to select the suitable candidates.
   - To guide MV surgical repair techniques, the Carpentier’s classification for rheumatic MR may be used.

Type I: Annular dilatation

In pure type I dysfunction, the main mechanism is rapid progressive dilatation of the left ventricle and mitral annulus caused by inflammatory pancarditis, which also frequently alters left ventricular contractility.

Type IIa: Anterior Leaflet Prolapse
On echocardiography, in true prolapse, the anterior leaflet overrides the mitral annulus plane during systole. Causes of true anterior leaflet prolapse are elongation or rupture of anterior primary chordae tendinae or elongation of the papillary muscles.

**Type II Anterior Leaflet Pseudoprolapse /III Posterior**

Mixed-type: pseudo IIa (anterior leaflet Pseudoprolapse) and IIIp (restricted posterior leaflet motion).

On echocardiography, contrary to pure type IIa dysfunction, in the mixed type pseudo IIa/IIIp, the anterior leaflet does not override the mitral annulus plane during systole but there is lack of coaptation, resulting mainly from significant restricted motion of the posterior leaflet, allowing for the anterior leaflet to move up to the annular plane during systole without overriding it.

**Type III: Restricted Leaflet Motion**

(Restricted anterior and/or posterior leaflet) dysfunction.

The restricted motion mainly affected the closure of the leaflets during systole, resulting in lack of leaflet coaptation generating mixed stenosis and regurgitation, either predominantly regurgitant (mitral orifice area >1.5 cm²), or stenotic (mitral orifice area < 1.5 cm²) on echocardiography.

In the majority of such cases, associated annular dilatation contributes to the degree of mitral regurgitation by aggravating the lack of coaptation between both mitral leaflets, as well as in the mixed type pseudo IIa/IIIp dysfunction.

There may be variable degrees of calcification and multi valvular involvement making valve repair difficult.(8)

**Prognosis after valve repair:**

- Even after successful valve repair, recurrence of RHD can occur despite strict adherence to penicillin prophylaxis. Patients with chronic RHD have persistently elevated inflammatory markers (cytokines and C-reactive protein) which indicate an ongoing inflammation that leads to failure of their valve repair.(9)
- Valve repair is superior to replacement, however, even after successful valve repair, long term follow up of patients showed that late mortality was 15%, and the reoperation rate was 27%, mainly related to the ongoing inflammation (10)
- Patients are usually living in distant areas and commonly fail to follow up and may have a wrong impression that their disease has been cured with the operation.
2. Percutaneous transvalvular mitral commissurotomy (PTMC):

- Patients with severe MS and suitable valve anatomy should be considered for PTMC or for closed mitral valvotomy (CMV), if PTMC is not available.

**Suitable valve:**

This may be assessed by scoring systems using the thickness, mobility, calcification and involvement of the subvalvular apparatus. The most commonly used are Wilkins and Cormier scores.

**Group 1 Cormier score is the most suitable** valve with pliable non-calcified anterior mitral leaflet and mild subvalvular disease.

**Contraindications:**

- Significant mitral regurgitation (> grade 2)
- Bilateral commissural calcification
- Left atria thrombus which is mobile or situated in a high risk position (on the atrial septum, protruding into the left atrial cavity, or obstructing the mitral valve orifice) presents a high likelihood of systemic embolism

**Relative contraindications**

- The presence of thrombus which is localized to the left atrial appendage
- Unilateral commissural calcification
- AV disease (AR may increase after MV dilatation so needs careful assessment) if the patient is with severe AV disease, AVR may be done with open commissurotomy.

**NB:** patients with LA thrombus which is not dissolved with anticoagulation may undergo open commissurotomy (open heart surgery to dilate the valve without replacing it)

Long term follow up after PTMC showed excellent results when patients with pliable valve and non calcified sub valve apparatus are chosen. The event free survival is up to 100% 4 years after the procedure. (11)

3. Valve replacement:
- Prosthetic valve replacement is the option when valve repair or commissurotomy is not feasible for MV disease and it is the main procedure for AV disease.
- The main problems related to valve replacement are the need for life-long anticoagulation and the risk of endocarditis. Both problems impose a huge burden on patients and the health system.
- It has been shown that prosthetic valve replacement in the presence of poor socio-economic conditions, and the presence of chronic inflammation together with preceding poor echocardiographic indices like low ejection fraction, all lead to a poor outcome. (12)
- Late mortality related to prosthetic valve like valve dysfunction, endocarditis, bleeding and cerebrovascular events are not uncommon especially in countries with low resources and poor health care system.

![Diagram: Choice of Prosthetic Valve]

**RHD in Adolescents:**

RHD typically affects older children, adolescents and young adults who bear most of the burden of chronic disease. The patients are faced with different challenges including the symptoms of heart failure with restriction of physical activity in this critical age, the need to take regular painful penicillin injections and the need for cardiac surgery and frequent hospital visits. All these factors may affect the adolescent’s physical and emotional attitudes leading to refusal and non compliance.

As with other chronic diseases, this category of patients need special attention and it is highly recommended to be managed in special clinics which addresses the psychological needs of adolescents.

Potential solutions include:
1. A team of young experts including psychologist
2. Peer groups with interactions through group discussions and youth activities e.g. in social media, games and songs.
3. Involving the patients in their management and encouraging them to give suggestions and solutions to their own problems.

**Infective Endocarditis:**
Infective endocarditis (IE) is an important complication of heart disease in general and valvular heart disease in particular. As RHD constitutes the major cause of valve disease in Africa, it is the most commonly encountered heart disease predisposing to IE.(13). In Sudan, RHD was found to be the underlying cardiac lesion in 40% of patients seen in a cohort of children with IE, and the mortality in this cohort was 20%. (14). IE needs to be considered whenever patients with RHD present with fever.

**Diagnosis of IE:**
Diagnosis should be guided by the Duke’s Criteria (15):

**Major criteria:**
1. Positive Echocardiogram:
   a. Oscillating intracardiac mass on valve or supporting structures in the path of regurgitant jets or on implanted material in the absence of an alternative anatomic explanation.
   b. Intramural abscess.
   c. New partial dehiscence of a prosthetic valve.
2. Histopathological evidence of IE from excised heart valve.
3. Positive blood culture with an organism consistent with IE.

**Minor criteria:**
1. Predisposing heart condition or IV drug use.
2. Fever.
4. Immunologic phenomena: glomerulonephritis, Osler nodes, Roth’s spots and positive rheumatoid factor.
5. Microbiological evidence: positive blood culture, but does not meet a major criterion.
6. Echocardiographic abnormalities that fell short of typical lesions described above.

In patients with RHD and fever: IE and recurrence of ARF need to be ruled out
Criteria for diagnosis:

**Definite IE:**
- 2 major criteria; or
- 1 major criterion and 2 minor criteria; or
- 5 minor criteria

**Possible IE**
- 1 major criterion and 1 minor criterion; or
- 3 minor criteria

**Rejected (one of the following)**
- Firm alternative diagnosis explaining the features of IE.
- Resolution of IE syndrome with antibiotic therapy for 4 days or less.
- No pathological evidence of IE at surgery or autopsy, with antibiotic therapy for 4 days or less; or Does not meet criteria for possible IE as above.

**Management:**
- Two blood samples should be taken for culture and sensitivity
- General investigations: Complete blood count, renal function, ESR, CRP.
- After taking blood culture, the patient should be started on antibiotics: the standard is benzyl penicillin (4-6 weeks) plus gentamicin (2 weeks)
- In case of prosthetic valve endocarditis, the drugs should include vancomycin
- Monitoring for progress and complications (systemic embolization)
- Surgical intervention may be needed if there is no improvement by medical treatment or there is a high risk of embolization (size, site and mobility of vegetation)

**Endocarditis Prophylaxis:**

Patients with RHD should be instructed to keep a good oral hygiene and avoid dental cares. If they are going for procedures associated with bactremia (e.g. dental, renal or other), antibiotic prophylaxis should be instituted one hour before the procedure.
Key Points:
1. Intervention in patients with RHD is a palliative but with good effect on morbidity and mortality
2. Asymptomatic patients with severe valve dysfunction should be assessed carefully by echocardiography in order to time intervention.
3. Conservation of the native valve when possible (Valve repair or commissurotomy) is preferred to valve replacement
4. Patients with prosthetic valve need close follow up to monitor anticoagulation and valve function
5. Strict BPG prophylaxis should be continued for life in patients with RHD even after surgical/cath interventions.
6. Fever in patients with RHD should alert physician to rule out endocarditis and recurrence of ARF

References:


6. Bonow, R., Carabello, BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of


Chapter 6
RHD in Pregnancy
RHD in Pregnancy:

**RHD**

Normal Pregnancy

- 30–50% increase in blood volume
- Reduction in systemic vascular resistance
- Tachycardia
- Increase in cardiac output.

- Exacerbation of heart Failure in regurgitating lesions
- Increase mitral stenosis gradient due to tachycardia and increased blood volume

RHD in Sudanese Pregnant Ladies:

In a review of 65 pregnant ladies with heart disease, RHD constituted 69% of causes of heart disease. Preconception counseling was available for only 10% of the patients. Maternal complications included arrhythmias (21%), heart failure (9%) and mortality (3%). Thirty percent had adverse fetal outcome including five cases of fetal loss. (1)

It is important to include RHD in maternal health program at MOH especially in areas with high prevalence.

**Preconception Counseling:**

The risks of anticoagulation during pregnancy should be clearly discussed

Ladies with the severe valve dysfunction are high risk and should be advised not to get pregnant. (see below)

**Mild – Moderate MR or AR:**

- Regurgitant lesions are better tolerated in pregnancy than obstructive lesions
- If regurgitation is more severe can present with CHF in 3rd trimester
- Angiotensin receptor antagonists and ACE inhibitors are **contraindicated during pregnancy.**
• Hydralazine and nitrates, or dihydropyridine calcium channel blockers (e.g., nifedipine) should be used if vasodilator therapy is needed; tachycardia is a common side effect.(2)
• Vaginal delivery spontaneously or assisted can be achieved in most patients
• Cardiac surgery should be avoided during pregnancy as fetal loss can occur in 30% (3)

**Mitral Stenosis:**
The most common type of RHD in pregnancy (4). Mild- moderate MS: diuretics, betablockers and digoxin to control the pregnancy induced tachycardia.

**Indication for PTMC:**
Symptomatic patients with severe MS and suitable mitral valve should go for PTMC at the end of the second or beginning of the third trimesters.(5)

**Classification of valvular heart disease risk in pregnancy**

**Low maternal and fetal risk**
- Asymptomatic AS with mean gradient <50 mmHg and normal LV function
- AR, NYHA Class I/II and normal LV function
- MR, NYHA Class I/II and normal LV function
- Mild–moderate MS, no severe pulmonary hypertension

**High maternal and fetal risk**
- Severe AS with or without symptoms
- AR and NYHA Class III or IV symptoms
- MS with NYHA Class II or higher
- MR with NYHA Class III or IV symptoms
- AV disease, MV disease, or both, resulting in severe pulmonary hypertension (PA pressure >75% systemic pressure)
- AV disease, MV disease, or both, with LV dysfunction (LVEF <40%)
- Reduced functional status (NYHA Class III or IV)

**High maternal risk**
- Impaired LV systolic function (LVEF <40%)
- Previous heart failure
- Previous CVA or TIA

**High neonatal risk**
- Maternal age <20 or >35 years
- Use of anticoagulant therapy throughout pregnancy
- Smoking during pregnancy
- Multiple gestations

Adapted from ref 6
Choice of anticoagulation Regimen:
The following regimens had been used with variable results:
- Un-fractionated heparin alone is associated with thrombo embolism in 25% of patients.
- Warfarin alone (keeping minimum dose) with or without aspirin then shifting to low molecular weight heparine (LMWH) at 36 weeks then to unfractionated heparine 36 hours before delivery.
- Heparin ceased 6 hours before and resumed 6 hours after cesarean section.
- Planned delivery and careful monitoring in peripartum period to avoid bleeding in the mother or baby. (7,8,9)

Pros and Cons of anticoagulation Regimens

- **Warfarin throughout pregnancy +/- aspirin:**
  - Crosses placenta with fetal embryopathy
  - Thrombo embolism 3-5%

- **Low molecular weight Heparin throughout pregnancy:**
  - Expensive
  - More thrombo embolism
  - Needs close monitoring
  - Bleeding

- **Low molecular weight Heparin and Warfarin:**
  - LMWH up to 13th Week then warfarin

Risks of anticoagulation during pregnancy:

**Maternal:**
1. Hypercoagulable state of pregnancy can lead to bleeding
2. Thromboembolism

**Fetal:**
1. Miscarriage
2. Fetal embryopathy
Key Points:

1. Pre-conception counseling of ladies with RHD is needed, patients in the high risk group should be advised not to get pregnant
2. Patients with moderate to severe regurgitation need to be on maximum anti-CHF drugs, **avoid angiotensin receptor blockers and ACE inhibitors**
3. Patients with moderate to severe MS need to be referred for PTMC
4. Patients with prosthetic valves need to be followed closely to determine the best anticoagulation and to monitor bleeding profile.
5. Delivery of patients with hemodynamically significant valve dysfunction should be planned with the cardiologist, anesthetist and intensivist involvement.

References:


Chapter 6
RHD Control Program
Tertiary

Secondary Prevention

Primary Prevention

Primordial Prevention

- Regular use of Benzathine PG
- Treatment of GAS pharyngitis
- Surveillance
- GAS Vaccine

- Improving Medical and surgical /cath management
- Improving living Conditions and access to healthcare
The previous Rheumatic Heart Disease Control Program: Lessons learned

In 1986-90, a World Health Organization (WHO) campaign involving 16 countries including Sudan was conducted in collaboration with the Sudanese MOH. The campaign aimed at screening and raising awareness with emphasis on secondary prophylaxis. Screening of 13322 children was done and 146 cases of RHD were reported in Khartoum Town (giving a prevalence of 10 per 1000). In this campaign Secondary prophylaxis coverage was found to be 72%. Phase II was planned to extend the program to other states, however more financial and technical support was needed in terms of logistics, surveillance and basic research; therefore this program stopped in 2000. (Data from a report by Dr.Nawal Kurdufani, and reference (1).

Lessons Learned from the Previous Program:

1. RHD control programs need to be modified to involve primary as well as secondary prevention.
2. More advocacy is needed, namely by involving local and international nongovernmental organizations (NGOs), the public and the patients.
3. More internal will and cooperation with regional organizations from countries with similarly high RHD prevalence are needed in order to assure continuity.

The current RHD Control Program

Mission and Vision

Mission:
To minimize the burden of acute rheumatic fever and rheumatic heart disease in Sudan

Vision:
Elimination of acute rheumatic fever and rheumatic heart disease

RHD Control Program Objectives and Description:

General Objective:
“To decrease the incidence of ARF and RHD by 25% in those less than 25 years by the year 2025”
This objective is derived from the World Heart Federation (WHF) position statement which is aligned with the World Health Organization’s 65th World Health Assembly, that includes a reduction in premature deaths from non-communicable diseases (NCDs) by 25% by the year 2025. (2,3)

Specific Objectives:

A. To increase the **awareness** about RHD in Khartoum and States endemic for RHD through structured programs directed to physicians, nurses, health workers, teachers and the public.

B. **Training** of health personnel including physicians, nurses, medical assistants in target areas.

C. Establishing a national **registry** for RHD.

D. Establishing **screening programs** for RHD for school children in Khartoum and target States.

E. Establishing strong **advocacy** through social, political and media channels.

F. Consolidation of **primary and secondary prevention** through awareness and training.

G. Ensuring the continuous supply of good **quality benzathine penicillin**.

H. To plan and conduct **research** that can have an impact on RHD control

I. To collaborate with national, regional and international **organizations** concerned with RHD control.

Description of the Current RHD Control Program:

In June 2012, the **Working Group on Pediatric Cardiology** and the **Sudan Heart Society** together with the **Sudanese Association of Pediatricians** initiated a program for RHD control that was conveyed to the MOH. It was based on **Awareness, Surveillance, Advocacy and Prevention (A.S.A.P.)** adopted from a program endorsed at the 1st All Africa Workshop on Rheumatic Fever and Rheumatic Heart Disease held in South Africa in October 2005. (3)

The ASAP program was convened by the Pan African Society of Cardiology (PASCAR), sponsored by the World Health Organization -Africa Office (WHO-AFRO), and the World Heart Federation (WHF). Similar programs based on primary prevention were adopted in India and Pacific Islands and had led to eradication of RHD in Cuba and Costa Rica. (4,5)

The main difference between ASAP and previous programs is that it is implementing **primary prevention of ARF** using clinical criteria for bacterial pharyngitis and treatment by single injection of benzathine penicillin.

The Tools for Achieving the Objectives of ASAP:

A. Robust **awareness raising campaigns** through utilizing different information, education communication means including **mass media**, printing of health education and promotional
materials, workshops and seminars as well as home and school visits. The main target group will be the population at most risk.

B. Training **workshops** for medical staff

C. Strengthening the early detection and surveillance system through **establishing more clinics and training physicians** in Khartoum and each of the target regions (Darfur, Kordofan, Gezira and White Nile) and **school screening** by auscultation and echocardiography.

D. Establishing regional and national **registries**.

E. Advocacy among the health professionals (through **workshops** and seminar) as well as among social and political groups through **media programs like films, radio and TV advertisement, street signs, mobile messages etc**. Also through attending **international meetings** and conferences.

All the above mentioned activities will be carried in close collaboration and coordination with national and state health authorities and related partners and associations.

**Components of a comprehensive RHD control program (Ref7)**
Integration:

RHD program will be implemented integrated with the following programs:

Non-Communicable Disease program (NCD)

Integrated Management of Childhood Illness (IMCI)

Mother and Child Health (MCH)

Adolescent’s Health

Monitoring:

The following parameters will be used for monitoring;

- Prevalence of RHD in school children before and after the program.
- Number of cases seen in outpatient of main hospitals
- Number of cases admitted to main hospitals
- Awareness of physicians, school staff and the public monitored by questionnaire before and after the start of the program.

Future Perspectives in RHD Control:

GAS Vaccine:

There has been extensive research to develop a vaccine against GAS. Currently vaccines are divided into M-Protein and non M-Protein types. M protein is the major determinant of the organism’s virulence. The 2 vaccines that have entered or are nearing clinical investigation are the N-terminal M protein basemultivalent vaccines (26-valent and 30-valent vaccines) and conserved M protein vaccines (the J8 vaccine and the StreptInCor vaccine). There are a variety of other vaccine candidates that are at various stages of discovery and development (8). There are major obstacles facing vaccine development including safety concerns, an incomplete understanding of immune protection in humans, inadequate epidemiological data and minimal development of combination antigen vaccines. It is expected that with more intensive efforts these obstacles can be overcome and a vaccine can be made available.
Key Points

1. Primary prevention is an important tool in the current RHD Control Program
2. Public awareness raising and training of health workers are needed
3. All society sectors concerned with RHD need to be involved (teachers, media, scientific and nongovernmental organizations) and should work in collaboration with health personnel to achieve the program targets.

References:


Appendices
Protocol for Management of Bacterial Pharyngitis

- Sore throat in the absence of runny nose and cough in patients 4-18 years is assumed to be bacterial pharyngitis.

Clinical Diagnosis of Bacterial Pharyngitis in Primary Health Care

1. Sore throat
2. 4-18 years old patient
3. No runny nose or cough

Treatment of Bacterial Pharyngitis:

ONE INJECTION of benzathine penicillin:
600 000 IU for less than 7 years old
1.2 million units if more than 7 years old
(see below dose and precautions)

- If patients are allergic to penicillin give erythromycin (see dose below)
- Oral antibiotics; ONLY IF THERE IS A CONTRAINDICATION OR SENSITIVITY TO PENICILLIN oral penicillin or amoxicillin for 10 WHOL DAYS.

Educate the family members about sore throat and the need to give benzathine penicillin

Refer patients to secondary care if there is:

1. Arthritis or severe arthralgia (prevent the patient from walking)
2. Palpitations
3. Shortness of breathing
4. Heart murmur
5. Chorea

**In patients diagnosed acute Rheumatic Fever:**
1. Instruct the family to give benzathine penicillin 3 weekly:
   - Up to 25 years of age if no rheumatic heart disease
   - FOR LIFE if there is rheumatic heart disease
2. Good dental hygiene.

---

**Continue benzathine penicillin3 weekly up to 25 years of age**
**(if no carditis) and for life (if there is rheumatic HD)**

See end of manual 2 Protocol of Benzathine Penicillin administration
Physician Manual 2

Federal Ministry of Health

Rheumatic Heart Disease Prevention Protocol

Manual 2

Secondary Prevention for Physicians
Protocol for Management of Acute Rheumatic Fever

(Secondary Prevention)

- Acute Rheumatic Fever (ARF) is diagnosed by

**The Jones Criteria: Modified 2015**

<table>
<thead>
<tr>
<th>Major Criteria: Five</th>
</tr>
</thead>
</table>

1. **Arthritis/arthralgia**: migratory, polyarthritis, monoarthritis or polyarthralgia

2. **Carditis**:
   - **A: Clinical carditis**: Typical murmurs:
     1. Pansystolic murmur at apex radiating to the axilla (mitral regurgitation)
     2. Mid diastolic apical murmur (Carry Coombs murmur) due to mitral valvulitis
     3. Early diastolic murmur at aortic area 2 associated with large volume pulse (aortic regurgitation)

   Murmurs may or may not be associated with:
   - Congestive heart failure (CHF)
   - Pericardial rub

   **B: Subclinical Carditis**: send patients with suspected ARF for echo as murmurs can be absent

3. **Chorea** (can be the only manifestation)

4. **Subcutaneous nodules**

5. **Erythema marginatum**
Minor Criteria: Four

1. Fever
2. Arthralgia: poly arthralgia is major criterion and monoarthralgia a minor one
3. Prolonged PR interval on ECG
4. Raised acute phase reactants (ESR, CRP, Total WBC count)

New patients are different from those with known rheumatic heart disease (RHD)

Diagnosis of ARF in New Patients

2 Major criteria OR

One major plus 2 minor criteria

Plus

Evidence of streptococcal infection (high or rising ASO)

Chorea alone is diagnostic of ARF

No need for aspirin

Treat by haloperidol or carbamazepine and start prophylaxis
Diagnosis of ARF in Patients known to have RHD

One major OR

2 minor criteria

Plus

Evidence of streptococcal infection (high or rising ASO)

Borderline (Probable) ARF

Patients with criteria not sufficient or atypical with positive ASO titer should be managed as ARF.

Management

1. Anti inflammatory:
   - Aspirin 75 mg per kilogram per day divided 6 hourly after meals for 4 weeks. Do ESR 2 weekly, taper aspirin by decreasing the dose by 2 tablet every week
   - Patients not responding (clinically and/or by acute phase reactants) or not tolerating aspirin can be started on prednisolone 2mg per kilogram per day for 2 weeks
   - then aspirin is added (dose 60 mg per kilogram per day) for another 2 weeks
   - then prednisolone is tapered & discontinued.
- Do ESR 2 weekly, taper aspirin by decreasing the dose by 2 tablets every week.

2. **Antibiotic:**
   One injection of benzathine penicillin *for treatment* then **regular 3 weekly benzathine penicillin** for secondary prophylaxis(dose and precautions below).

3. **Duration of prophylaxis:**
   - Patients without carditis: till 25 years of age.
   - Patients with carditis: For life

4. Carditis: if there is heart failure start *furosemide 1-2 mg per kilogram per day.*

   **Consult cardiologist**

5. Bed rest: 4 weeks

6. **NOTIFY** the Ministry of Health, National Program of RHD Control.

   7. Ask about family members: those with sore throat are given one injection of benzathine or oral antibiotics for 10 days.

   8. Bacterial endocarditis prophylaxis: for those with valve lesions going for procedures leading to bactremia, e.g. dental procedures give one dose of amoxicillin 50mg/kg one hour prior to procedure.

9. Family education:

   **Continue benzathine penicillin** 3 weekly up to 25 years of age (if no carditis) and for life (if there is rheumatic HD)

   **Sore throat can lead to serious heart damage**

   **Good dental hygiene prevents complications of heart disease**
Appendix:

How to give Benzathine Penicillin

The Penicillin Kit

Penicillin vial
Lidocaine
Antihistamine
Adrenaline
2 needles (one for sensitivity test one for injection)
10 ml syringe

1. Ask about history of penicillin allergy
2. If there is history of penicillin allergy do a Prick skin test

Prick skin test

- Dilute one vial in 10 ml distilled water
- Take 0.1 ml and add 10 ml to it (penicillin diluted 100 times)
- Scratch the skin with 0.1 ml of this solution
- Wait for 20 minutes
- Positive test: redness, wheal or itching

- If prick test is **positive**: Don’t give penicillin
- **Dose**: >7 years: 1.2 million units
- < 7 years: 600 000 units
- If prick test is **negative**: do an intradermal sensitivity test.

Intradermal Skin Test

Has to be done before each injection

1. Dilute penicillin (1.2 million units) in 10 ml distilled water
2. Inject 0.2 ml intradermally to form 2-3 mm wheal
3. Wait for 20 minutes
4. Positive test: wheal 5 mm or more with redness, itching
NEVER GIVE INJECTION IN PATIENTS WITH POSITIVE TEST

NO SENSITIVITY: GIVE INJECTION DEEP IN GLUTEAL MUSCLE

Penicillin can be diluted in lidocaine to decrease pain

If sensitivity test is negative: give the injection deep in gluteal muscle, make sure not intravenous.

If an allergic reaction develops: local reaction like skin irritation: Antihistamine injection

Systemic reaction: hypotension: Immediate adrenalin, antihistamine and intravenous fluids and refer for higher center.

In case of penicillin sensitivity:

Erythromycin BD for 10 days (for treatment) and for the duration of secondary prophylaxis

Dose:

Less than 7 years: 250 mg BD for 10 days (for treatment) and for the duration of secondary prophylaxis

More than 7 years: 500 mg BD for 10 days (for treatment) and for the duration of secondary prophylaxis.
Medical Assistant Manual:

برنامج مكافحة روماتزم القلب
وزارة الصحة الاتحادية
إدارة الرعاية الصحية الأساسية
الأمراض غير السارية

علاج التهاب الحلق البكتيري و الحمى الروماتزمية

الرسائل الأساسية:
1. التهاب الحلق البكتيري يؤدي إلى الحمى الروماتزمية
2. الحمى الروماتزمية تؤدي إلى روماتزم القلب الذي يدمر صمامات القلب و لا يمكن علاجه

التشخيص:
1. آلام الحلق الحادة في عمر 4 سنوات إلى 18 سنة
2. لا توجد نزلة (فحة، جريان الأنف)

العلاج:

حقنة (واحدة) البنسلين طويل الأجل:

بعد اختبار الحساسية (ملحق)

- 600,000 وحدة: أقل من 7 سنوات
- 1,200,000 وحدة: أكثر من 7 سنوات

في حالة حساسية البنسلين:

للأطفال أقل من 7 سنوات: ارثرومايسين: 250 ملجم بالفم صباح ومساء لمدة 10 أيام
للأطفال أكثر من 7 سنوات: ارثرومايسين: 500 ملجم بالفم صباح ومساء لمدة 10 أيام

أعراض الحمى الروماتزمية

ورم بالمفاصل الكبيرة
ألم حاد بالمفاصل الكبيرة
ضربات قلب سريعة
ضيق التنفس
حركات لا إرادية

مرضى تم تشخيص الحمى الروماتزمية من قبل الطبيب

- يجب متابعة حقنة البنسلين طويل الأجل (نفس الجرعة أعلاه) كل 21 يوم بانتظار.
- حقنة البنسلين كل 21 يوم تمنع تدمير الصمام.

 يجب التأكد من عدم اهمال مريض الحمى الروماتزمية بحقنة البنسلين كل 21 يوم.
كيفية حقن البنسلين طويل الأجل:

اسأل المريض: هل تعاني من حساسية البنسلين؟
1. نعم: استدع الطبيب لعمل اختبار سطحي
2. لا (أو غير متأكد): أقوم بعمل اختبار عميق

اختبار الحساسية العميق:

يجب إجراؤه قبل كل حقنة

يحل الفتيل في كمية الماء المحددة

يأخذ 2 خط

يحقن تحت الجلد حتى تتكون بقعه مساحتها 2-3 ملی متر

توجه علامة بالفلام حول منطقة الحقنة

ينتظر 20 دقيقة

الموجب: وجود بقعة مرتفعة مساحتها 5 ملی متر أو أكثر

لا تعطي الحقن ابدا في حالة الاختبار الموجب

عند ظهور هذه الأعراض:

حكة شديدة بالجلد: اعطي حقنة (إنتي هستامين) - استدع الطبيب

هبوط بالجسم أو ضيق بالتنفس: اعطي حقنة ادرينالين - استدع الطبيب

كيف نعطي الحقن:

- استعمل إبرة جديدة واحظ في عضلة الالية بعمق . إسحب أولا لتجنب الوريد ثم أفرغ الدواء

إنتبه: اعطاء حقن البنسيلين طويل الأجل في الوريد يؤدي إلى الوفاة
Teacher’s Manual
Public Awareness Posters:

وجع الحلق في عمر 4 إلى 18 سنة (بدون نزله) يشير خطر لانه يودي إلى روماتزم القلب.

علاج ووجع الحلق (بدون نزله) هو حقن إ واحدة بنبضين طويل المفعول.

تأخير علاج ووجع الحلق يؤدي إلى وقع المفاصل.

تورم المفاصل مرضا خطيرا يجب متابعته الطبيب فورا. تأخير العلاج يؤدي إلى تدمير صمامات القلب.

وجع المفاصل يدمر صمامات القلب.

حقنة البنسان تنقذ القلب.
RHD Educational Websites:

Sudanese Children’s Heart Society:
http://www.sudankidsheart.org/

World Heart Federation- RHD Net:

Australian RHD Guidelines

TIPPS

Wi Red

http://www.wiredhealthresources.net/EchoProject/

تم بحمد الله

Last updated: September 15/2015